{"filing":{"accession_number":"0001824293-26-000057","cik":"0001824293","ticker":"GRI","company_name":"GRI Bio, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"val-20260908.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429326000057/val-20260908.htm"},"events":[{"id":31830,"run_id":29229,"accession_number":"0001824293-26-000057","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"GRI Bio announced positive Phase 2a translational biomarker data from its GRI-0621 (oral tazarotene) study in idiopathic pulmonary fibrosis patients, demonstrating proof-of-concept across multiple mechanistic pillars (immune rebalancing, fibrolysis, lung repair, antitussive, GI-protection) and supporting advancement toward a pivotal Phase 2b/3 adaptive study.","company_name":"GRI Bio, Inc.","ticker":"GRI","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":34839,"accession_number":"0001824293-26-000057","item_number":"7.01","item_title":"Regulation FD","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"GRI Bio posted an updated corporate presentation to its investor relations website on September 8, 2026, disclosed under Item 7.01 (Regulation FD). The presentation contains forward-looking statements about the company's drug development pipeline (GRI-0621 for IPF, GRI-0803 for SPMS/SLE) and Phase 2a clinical data. This is a routine disclosure of investor materials—a corporate presentation—that does not constitute a material event triggering a specific 8-K category. While the presentation discusses clinical trial results and development timelines, the filing itself is merely furnishing existing presentation materials for informational purposes, not announcing a material corporate event, financial result, or strategic change.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:19:02.499801+00:00","company_name":"","ticker":null,"filing_date":""},{"id":34840,"accession_number":"0001824293-26-000057","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"GRI Bio announced positive Phase 2a translational biomarker data from its GRI-0621 (oral tazarotene) study in idiopathic pulmonary fibrosis patients. The disclosure centers on clinical trial progress and mechanistic biomarker findings supporting advancement toward a pivotal Phase 2b/3 adaptive study. This is a material operational/clinical milestone for a biotech company, as it demonstrates proof-of-concept across multiple mechanistic pillars (immune rebalancing, fibrolysis, lung repair, antitussive, GI-protection) and supports the regulatory pathway forward, but does not constitute a formal earnings release, M\u0026A activity, or other specifically-defined event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:19:02.499801+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34839,"accession_number":"0001824293-26-000057","item_number":"7.01","item_title":"Regulation FD","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.75,"reasoning":"GRI Bio posted an updated corporate presentation to its investor relations website on September 8, 2026, disclosed under Item 7.01 (Regulation FD). The presentation contains forward-looking statements about the company's drug development pipeline (GRI-0621 for IPF, GRI-0803 for SPMS/SLE) and Phase 2a clinical data. This is a routine disclosure of investor materials—a corporate presentation—that does not constitute a material event triggering a specific 8-K category. While the presentation discusses clinical trial results and development timelines, the filing itself is merely furnishing existing presentation materials for informational purposes, not announcing a material corporate event, financial result, or strategic change.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:19:02.499801+00:00","company_name":"GRI Bio, Inc.","ticker":"GRI","filing_date":"2026-09-08"},{"id":34840,"accession_number":"0001824293-26-000057","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"GRI Bio announced positive Phase 2a translational biomarker data from its GRI-0621 (oral tazarotene) study in idiopathic pulmonary fibrosis patients. The disclosure centers on clinical trial progress and mechanistic biomarker findings supporting advancement toward a pivotal Phase 2b/3 adaptive study. This is a material operational/clinical milestone for a biotech company, as it demonstrates proof-of-concept across multiple mechanistic pillars (immune rebalancing, fibrolysis, lung repair, antitussive, GI-protection) and supports the regulatory pathway forward, but does not constitute a formal earnings release, M\u0026A activity, or other specifically-defined event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:19:02.499801+00:00","company_name":"GRI Bio, Inc.","ticker":"GRI","filing_date":"2026-09-08"}]}